At a glance

What is BPC-157?

BPC-157, short for “Body Protection Compound-157,” is a synthetic pentadecapeptide¹, a chain of 15 amino acids (sequence GEPPPGKPADDAGLV). It is a lab-made fragment modeled on a larger protective protein that occurs naturally in human gastric juice, the acidic fluid the stomach uses to break down food.

Unlike a hormone such as insulin, BPC-157 does not appear to act on a single, well-defined receptor. Researchers instead describe it as a “cytoprotective” agent², meaning a molecule associated with protecting and maintaining the integrity of cells and tissue in laboratory and animal models.

BPC-157 has never been approved as a medicine through the FDA.

The history of BPC-157

The idea behind BPC-157 dates to 1975, when a Croatian medical student named Predrag Sikiric attended a lecture on the body’s stress response at the University of Zagreb. He reasoned that if stress can damage the stomach, the stomach might also produce its own protective substance.

By 1983, Sikiric had assembled a team that collected human and animal gastric juice from hospitals, emergency rooms, and slaughterhouses to search for the active ingredient. In 1989, the group isolated a 15 amino acid peptide called BPC-157. The name and number carried personal and patriotic meaning for Sikiric during a turbulent period in Croatia’s history, as described in a 2026 STAT News profile³ of the researcher.

From 1993, the Zagreb pharmaceutical company PLIVA, later working with Parke-Davis, developed the peptide and ran early animal studies along with two small human trials for ulcerative colitis in the early 2000s. The second of those trials reported a positive effect that did not reach statistical significance. After GlaxoSmithKline acquired PLIVA’s research institute in 2006, the program was shelved, and the rights returned to Sikiric in 2009.

Without a pharmaceutical company continuing its development, BPC-157 followed an unusual path. Around 2010, it spread through online forums and Sikiric’s published papers, and suppliers began selling it directly. It has circulated as a research chemical ever since. Most of the underlying studies still come from Sikiric’s own laboratory. A 2025 systematic review⁴ identified 544 BPC-157 articles published between 1993 and 2024, most of them from a small number of research groups.

The only registered interventional human trial of BPC-157 was a small Phase I safety study of oral tablets (NCT02637284⁵) run in Tijuana, Mexico around 2015 and 2016. It was never completed to publication and remains listed with an “unknown” status and no posted results, so even its basic safety findings in humans were never independently reported.

How does BPC-157 work?

The proposed mechanisms come almost entirely from animal and cell studies. The most consistent finding is that BPC-157 promotes angiogenesis², the growth of new blood vessels, mainly through the VEGFR2-Akt-eNOS pathway and by influencing the nitric oxide system, which helps regulate blood flow and vascular health.

In laboratory models, researchers have also reported that BPC-157 increases collagen production, activates fibroblasts, reduces inflammatory signaling, and affects pain pathways¹. In tendon cells, it has been shown to increase expression of the growth hormone receptor. Across rodent studies, it has been associated with faster healing of muscle, tendon, ligament, bone, and gastrointestinal tissue.

In animal data, BPC-157 is metabolized in the liver, cleared by the kidneys, and has a short half-life of under 30 minutes⁴. None of these findings have been confirmed in controlled human studies.

Is BPC-157 FDA-approved?

No, BPC-157 has never been approved by the FDA, or any comparable regulator, for any condition, and it has not completed the controlled human trials that approval requires.

Its regulatory status has also changed several times:

• 2023: The FDA placed BPC-157 in Category 2 of its interim 503A bulk drug substances list⁶, the category for substances that may present significant safety risks, which restricted compounding pharmacies from making it.
• April 2026: The FDA removed BPC-157 from that category because the nominators withdrew their nominations⁷. BPC-157 is still not on the 503A bulks list or in Category 1.
• July 23, 2026: Its Pharmacy Compounding Advisory Committee voted in favor⁸ of allowing the peptide to be compounded, meaning prepared for individual patients by licensed compounding pharmacies rather than mass-produced and sold as a standardized, FDA-approved drug.
• October 28, 2026: The FDA granted enforcement discretion¹³ allowing 503A compounding pharmacies to compound six peptides, including BPC-157, while the formal rulemaking to add them to the 503A bulks list is still pending.

Licensed pharmacies may now prepare BPC-157 for individual patients, but it is still not an FDA-approved drug: enforcement discretion is a decision not to pursue enforcement rather than an approval, it was issued with no stated end date, and it does not reflect any new finding that BPC-157 is safe or effective.

BPC-157 is also prohibited at all times in sport⁹ under the World Anti-Doping Agency’s S0 category for non-approved substances.

What does the research show?

The research on BPC-157 is overwhelmingly preclinical. The 2025 systematic review in orthopedic sports medicine screened the literature and included 36 studies, of which 35 were preclinical (animal or laboratory) and only one involved humans⁴. There are no completed randomized controlled human trials, and there is no long-term human data.

A 2019 review¹⁰ reached a similar conclusion, describing consistent healing effects in rodents while noting that efficacy is “yet to be confirmed in humans.” The animal research is broad and fairly consistent, but the human research needed to draw firm conclusions has not been done.

The most replicated animal findings involve tendons. In rats with a cut Achilles tendon, BPC-157 improved tendon strength, elasticity, and function¹¹ and shrank the defect by day 14.

The one human report is a retrospective, uncontrolled series of 12 patients with chronic knee pain. After a single knee injection, seven of them (58%) reported relief lasting more than 6 months⁴. The report published no effect size or safety data.

What is the difference between BPC-157 and TB-500?

BPC-157 is often mentioned alongside TB-500, a synthetic fragment of the protein thymosin beta-4. The two share several features. Both are peptides, unapproved by the FDA, prohibited in sports, and have been studied mainly in animals rather than in humans.

The differences are largely mechanistic:

Neither has controlled human evidence.

More for digestive & weight